Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

A recent clinical trial shows that a proportion of lung cancer patients carrying the EGFR T790M mutation develop resistance to osimertinib. In this study, the authors show that T790M subclonality is associated with worse clinical outcome likely through co-occurring PIK3CA alterations, which can be t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tereza Vaclova, Ursula Grazini, Lewis Ward, Daniel O’Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan Hartmaier, Kenneth S. Thress, Paul D. Smith, J. Carl Barrett, Julian Downward, Elza C. de Bruin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/481ad63fcd374f3eb7bb421d24c7891e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:481ad63fcd374f3eb7bb421d24c7891e
record_format	dspace
spelling	oai:doaj.org-article:481ad63fcd374f3eb7bb421d24c7891e2021-12-02T17:04:54ZClinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers10.1038/s41467-021-22057-82041-1723https://doaj.org/article/481ad63fcd374f3eb7bb421d24c7891e2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22057-8https://doaj.org/toc/2041-1723A recent clinical trial shows that a proportion of lung cancer patients carrying the EGFR T790M mutation develop resistance to osimertinib. In this study, the authors show that T790M subclonality is associated with worse clinical outcome likely through co-occurring PIK3CA alterations, which can be targeted by PI3K pathway inhibitors.Tereza VaclovaUrsula GraziniLewis WardDaniel O’NeillAleksandra MarkovetsXiangning HuangJuliann ChmieleckiRyan HartmaierKenneth S. ThressPaul D. SmithJ. Carl BarrettJulian DownwardElza C. de BruinNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Tereza Vaclova Ursula Grazini Lewis Ward Daniel O’Neill Aleksandra Markovets Xiangning Huang Juliann Chmielecki Ryan Hartmaier Kenneth S. Thress Paul D. Smith J. Carl Barrett Julian Downward Elza C. de Bruin Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
description	A recent clinical trial shows that a proportion of lung cancer patients carrying the EGFR T790M mutation develop resistance to osimertinib. In this study, the authors show that T790M subclonality is associated with worse clinical outcome likely through co-occurring PIK3CA alterations, which can be targeted by PI3K pathway inhibitors.
format	article
author	Tereza Vaclova Ursula Grazini Lewis Ward Daniel O’Neill Aleksandra Markovets Xiangning Huang Juliann Chmielecki Ryan Hartmaier Kenneth S. Thress Paul D. Smith J. Carl Barrett Julian Downward Elza C. de Bruin
author_facet	Tereza Vaclova Ursula Grazini Lewis Ward Daniel O’Neill Aleksandra Markovets Xiangning Huang Juliann Chmielecki Ryan Hartmaier Kenneth S. Thress Paul D. Smith J. Carl Barrett Julian Downward Elza C. de Bruin
author_sort	Tereza Vaclova
title	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
title_short	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
title_full	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
title_fullStr	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
title_full_unstemmed	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
title_sort	clinical impact of subclonal egfr t790m mutations in advanced-stage egfr-mutant non-small-cell lung cancers
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/481ad63fcd374f3eb7bb421d24c7891e
work_keys_str_mv	AT terezavaclova clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT ursulagrazini clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT lewisward clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT danieloneill clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT aleksandramarkovets clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT xiangninghuang clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT juliannchmielecki clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT ryanhartmaier clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT kennethsthress clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT pauldsmith clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT jcarlbarrett clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT juliandownward clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers AT elzacdebruin clinicalimpactofsubclonalegfrt790mmutationsinadvancedstageegfrmutantnonsmallcelllungcancers
_version_	1718381789073899520

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

Ejemplares similares